S&P 500   5,077.43 (+0.15%)
DOW   38,885.64 (-0.16%)
QQQ   437.14 (+0.43%)
AAPL   179.93 (-0.82%)
MSFT   408.19 (+0.12%)
META   485.90 (+0.39%)
GOOGL   136.90 (+0.38%)
AMZN   174.75 (+0.92%)
TSLA   199.92 (-1.05%)
NVDA   790.09 (+1.73%)
NIO   5.63 (+3.68%)
AMD   188.24 (+6.63%)
BABA   74.15 (-0.59%)
T   16.98 (+0.12%)
F   12.37 (+0.57%)
MU   89.53 (-0.20%)
CGC   3.30 (-1.79%)
GE   155.67 (+0.04%)
DIS   111.40 (+0.54%)
AMC   4.37 (-12.42%)
PFE   26.71 (-1.22%)
PYPL   60.10 (-0.25%)
XOM   104.78 (+0.44%)
S&P 500   5,077.43 (+0.15%)
DOW   38,885.64 (-0.16%)
QQQ   437.14 (+0.43%)
AAPL   179.93 (-0.82%)
MSFT   408.19 (+0.12%)
META   485.90 (+0.39%)
GOOGL   136.90 (+0.38%)
AMZN   174.75 (+0.92%)
TSLA   199.92 (-1.05%)
NVDA   790.09 (+1.73%)
NIO   5.63 (+3.68%)
AMD   188.24 (+6.63%)
BABA   74.15 (-0.59%)
T   16.98 (+0.12%)
F   12.37 (+0.57%)
MU   89.53 (-0.20%)
CGC   3.30 (-1.79%)
GE   155.67 (+0.04%)
DIS   111.40 (+0.54%)
AMC   4.37 (-12.42%)
PFE   26.71 (-1.22%)
PYPL   60.10 (-0.25%)
XOM   104.78 (+0.44%)
S&P 500   5,077.43 (+0.15%)
DOW   38,885.64 (-0.16%)
QQQ   437.14 (+0.43%)
AAPL   179.93 (-0.82%)
MSFT   408.19 (+0.12%)
META   485.90 (+0.39%)
GOOGL   136.90 (+0.38%)
AMZN   174.75 (+0.92%)
TSLA   199.92 (-1.05%)
NVDA   790.09 (+1.73%)
NIO   5.63 (+3.68%)
AMD   188.24 (+6.63%)
BABA   74.15 (-0.59%)
T   16.98 (+0.12%)
F   12.37 (+0.57%)
MU   89.53 (-0.20%)
CGC   3.30 (-1.79%)
GE   155.67 (+0.04%)
DIS   111.40 (+0.54%)
AMC   4.37 (-12.42%)
PFE   26.71 (-1.22%)
PYPL   60.10 (-0.25%)
XOM   104.78 (+0.44%)
S&P 500   5,077.43 (+0.15%)
DOW   38,885.64 (-0.16%)
QQQ   437.14 (+0.43%)
AAPL   179.93 (-0.82%)
MSFT   408.19 (+0.12%)
META   485.90 (+0.39%)
GOOGL   136.90 (+0.38%)
AMZN   174.75 (+0.92%)
TSLA   199.92 (-1.05%)
NVDA   790.09 (+1.73%)
NIO   5.63 (+3.68%)
AMD   188.24 (+6.63%)
BABA   74.15 (-0.59%)
T   16.98 (+0.12%)
F   12.37 (+0.57%)
MU   89.53 (-0.20%)
CGC   3.30 (-1.79%)
GE   155.67 (+0.04%)
DIS   111.40 (+0.54%)
AMC   4.37 (-12.42%)
PFE   26.71 (-1.22%)
PYPL   60.10 (-0.25%)
XOM   104.78 (+0.44%)
NASDAQ:IMRA

IMARA (IMRA) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$6.32
$25.28
52-Week Range
N/A
Volume
271,700 shs
Average Volume
138,364 shs
Market Capitalization
$165.80 million
P/E Ratio
126.40
Dividend Yield
N/A
Price Target
N/A

IMRA stock logo

About IMARA Stock (NASDAQ:IMRA)

IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2-related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.


IMRA Stock News Headlines

Imara Blume
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
Imara 10% Owner Trades $336K In Company Stock
Rare Earth Elements: The Workhorse of The Tech Revolution
They're the most underrated yet crucial elements of technology. From renewable energy to military defense, Rare Earths are essential pieces of modern technology. Global superpowers and savvy investors are quickly learning just how valuable they truly are.
Form 8-K IMARA Inc. For: Oct 13 - StreetInsider.com
See More Headlines
Receive IMRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IMARA and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
2/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMRA
Phone
N/A
Fax
N/A
Employees
41
Year Founded
N/A

Profitability

Net Income
$1.49 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.44 per share

Miscellaneous

Free Float
16,449,000
Market Cap
$165.80 million
Optionable
Not Optionable
Beta
1.09
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Rahul D. Ballal Ph.D. (Age 44)
    Pres, CEO & Director
    Comp: $761.55k
  • Mr. Michael P. Gray MBA (Age 51)
    CPA, CFO & COO
    Comp: $641.24k
  • Mr. Stephen M. Migausky J.D.
    Sr. VP of Legal & Gen. Counsel














IMRA Stock Analysis - Frequently Asked Questions

How were IMARA's earnings last quarter?

IMARA Inc. (NASDAQ:IMRA) announced its quarterly earnings data on Tuesday, November, 9th. The company reported ($2.20) EPS for the quarter, topping analysts' consensus estimates of ($3.64) by $1.44. During the same period last year, the business earned ($2.88) earnings per share.

When did IMARA's stock split?

IMARA shares reverse split before market open on Friday, February 24th 2023. The 1-4 reverse split was announced on Friday, February 24th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

What other stocks do shareholders of IMARA own?
When did IMARA IPO?

(IMRA) raised $76 million in an initial public offering on Thursday, March 12th 2020. The company issued 4,500,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Citigroup and SVB Leerink served as the underwriters for the IPO.

This page (NASDAQ:IMRA) was last updated on 2/29/2024 by MarketBeat.com Staff